Opendata, web and dolomites

ORTHOCAT SIGNED

Bioorthogonal Photocatalytic Activation of Metal-Based Prodrugs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ORTHOCAT project word cloud

Explore the words cloud of the ORTHOCAT project. It provides you a very rough idea of what is the project "ORTHOCAT" about.

trigger    potentially    chem    accomplishes    homeostasis    accumulate    intimately    death    successful    tumour    dna    once    employing    original    mitochondrial    photocatalyst    organelle    tumours    agents    simultaneously    mission    efficiency    transition    2017    vectors    photochemistry    complexes    photodynamic    light    combines    catalytic    strategy    photocatalytic    singlet    action    metal    synergistically    oxygen    anticancer    designing    selectivity    therapy    mitochondria    prodrugs    mechanism    reducing    fewer    cancer    innovative    activation    kill    unconventional    inside    pdt    wellbeing    surgery    vast    strategies    limits    involve    prodrug    4619    dual    act    efficacy    triphenylphosphonium    drugs    therapeutic    depends    photosensitizer    riboflavin    solid    framework    species    orthocat    clinics    effectiveness    generate    hypoxic    pt    nevertheless    convenient    selectively    proposes    cell    activating    multidisciplinary    nanoplatforms    photochemotherapy    class    outcome    new    background    imbalance    photoactivatable    care    cellular    sci    redox    compounds    patient    cells    delicate   

Project "ORTHOCAT" data sheet

The following table provides information about the project.

Coordinator
FUNDACION DONOSTIA INTERNATIONAL PHYSICS CENTER 

Organization address
address: PASEO MANUEL LARDIZABAL 4
city: DONOSTIA SAN SEBASTIAN
postcode: 20018
website: http://dipc.ehu.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-09-10   to  2020-09-09

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION DONOSTIA INTERNATIONAL PHYSICS CENTER ES (DONOSTIA SAN SEBASTIAN) coordinator 158˙121.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

New cancer care methodologies with fewer side effects and no need for major surgery are required to enhance patient wellbeing. Photodynamic Therapy (PDT) partially accomplishes such mission employing light and a photosensitizer. Nevertheless, the PDT mechanism of action intimately depends on oxygen, which limits its efficacy, particularly in hypoxic solid tumours. Promising strategies to improve the impact of PDT in the clinics currently involve the design of photoactivatable transition metal complexes, a class of compounds which combines the rich photochemistry of metal complexes with the vast background of metal-based drugs in cancer therapy.

In this framework, ORTHOCAT proposes an original and multidisciplinary strategy to exploit the efficiency and selectivity of riboflavin as unconventional photocatalyst for the activation of Pt(IV) anticancer prodrugs (Chem. Sci. 2017, 8, 4619).

The project aims at designing novel riboflavin-based catalytic systems capable of activating Pt(IV) anticancer prodrugs inside the mitochondria of tumour cells. In particular, I will use triphenylphosphonium targeting vectors to develop new photocatalytic prodrug systems and delivery nanoplatforms which selectively accumulate in the mitochondria. Once in the organelle, riboflavin will act as singlet oxygen photosensitizer for PDT and simultaneously as photocatalyst to generate Pt(II) species for targeting mitochondrial DNA (photochemotherapy). Imbalance of mitochondrial delicate redox homeostasis by ORTHOCAT dual agents can trigger cell death through convenient cellular pathways. Therefore, ORTHOCAT prodrug systems will synergistically kill cancer cells with increased effectiveness, while potentially reducing side effects of metal-based drugs. Successful outcome of the project has the potential to deliver innovative therapeutic agents for cancer photochemotherapy.

 Deliverables

List of deliverables.
Data Management Plan Open Research Data Pilot 2019-08-05 15:14:49

Take a look to the deliverables list in detail:  detailed list of ORTHOCAT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORTHOCAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORTHOCAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Migration Ethics (2019)

Migration Ethics

Read More  

EcoSpy (2018)

Leveraging the potential of historical spy satellite photography for ecology and conservation

Read More  

DEAP (2019)

Development of Epithelium Apical Polarity: Does the mechanical cell-cell adhesions play a role?

Read More